Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Nicholas J. Vogelzang

Dr. Nicholas J. Vogelzang

Chair and Medical Director of the Developmental Therapeutics Committee, Co-Chair of the Genitourinary Committee for U.S. Oncology Research, Medical Oncologist

In 2002, Dr. Nicholas J. Vogelzang launched a clinical trial testing a drug called pemetrexed for mesothelioma patients. The trial would become the largest Phase 2 pemetrexed study with mesothelioma patients to date.

Get in touch
Jump to a Topic:

About Nicholas J. Vogelzang

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Team Leader icon

    Team Leader

  • Board Certified icon

    Board Certified in Medical Oncology

  • Board Certified icon

    Board Certified in Internal Medicine

At the end of the trial, over 41 percent of patients experienced a reduction in their tumors. The patients who took pemetrexed with an additional chemotherapeutic drug called cisplatin also extended their survival rate by three months.

Vogelzang also was involved with clinical trials for Alimta, the first and only drug that the FDA approved to treat mesothelioma. These studies revolutionized mesothelioma treatment and brought about a new standard of chemotherapeutic care. Vogelzang explained these therapies, as well as the causes and other approaches to mesothelioma treatment, as the editor of “Malignant Mesothelioma,” a comprehensive clinical textbook.

Emergent Therapies for Mesothelioma

As a chair and medical director for the Developmental Therapeutics Committee, Vogelzang’s work with emergent therapies has allowed numerous mesothelioma patients to extend their lifespan and reduce the symptoms of their rare cancer.

Doctor talking to patients

Talk to a Doctor About Your Diagnosis

We can help you or a loved one get in contact with Dr. Vogelzang and find the treatment that's best for you.

Get Started Today

In 2006 the Mesothelioma Applied Research Foundation (MARF) named Vogelzang as the board chair for his involvement with the search for a mesothelioma cure. When he took the position, he explained the ambitious mission he hoped to lead:

Dr. Vogelzang

Together in the coming years, we will increase our impact on overcoming the meso tragedy.”

Vogelzang incorporates lessons he learned in the laboratory to his clinical practice at the Comprehensive Cancer Centers of Nevada (CCCN). He has served as a medical oncologist at the facility since 2009, where each patient is provided with a comprehensive team of specialists at a single location.

Before joining the CCCN, Vogelzang worked as the founding director of the Nevada Cancer Institute. He also directed the University of Chicago Research Center from 1999 to 2003. He has served on a number of committees, including the American Society of Clinical Oncology and the Illinois Division of the American Cancer Society.

Quick Fact:

Dr. Vogelzang was the first professor to be named the Fred C. Buffet Professor in Medicine at the University of Chicago.

Vogelzang’s internship, residency and chief residency were all completed at Rush-Presbyterian-St. Luke’s Medical Center after he finished medical school at the University of Illinois. He has written more than 435 scientific publications since entering the medical field in 1974.

See More Top Mesothelioma Doctors

Dr. Nicholas Vogelzang’s Publications

Of more than 100 scholarly articles, 19 of Vogelzang’s publications address mesothelioma. These works include “Chemotherapy for Malignant Mesothelioma,” published in the May 2008 issue of Lancet, and “Newer Issues in Mesothelioma Chemotherapy,” published in the Journal of Thoracic Oncology.

Disclaimer: Dr. Nicholas J. Vogelzang has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.


Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 19, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now